title: Effect of histone deacetylase on prostate carcinoma.
abstract: Commonly occurred in aged males, the incidence of prostate carcinoma is increasing by years. Histone deacetylase (HDACs) as one key enzyme in regulating gene transcription has been found to be related with cancer occurrence. Trichostatin A (TSA) is one HDAC inhibitor for suppressing tumor growth. This study thus treated prostate carcinoma cell line PC3 with TSA, to analyze the effect of HDAC on the occurrence and progression of HDAC. PC3 cells were treated with gradient concentrations of TSA. MTT assay was employed to detect the proliferation of PC3 cells, while flow cytometry was used to detect the cell apoptosis and cell cycle. Apoptotic proteins including caspase-3, caspase-9 and bcl-2 were further quantified by Western blotting. MTT assays showed a dose- and time-dependent manner of TSA in inhibiting PC3 cell proliferation. Most of PC3 cells were arrested at G1 phase after treating with TSA. The apoptotic ratio of cells was also elevated by higher concentrations of drugs. Apoptotic proteins including caspase-3, caspase-9 and bcl-2 were all up-regulated by TSA. HDAC inhibitor can effectively suppress the proliferation of prostate carcinoma cells, which can be arrested at G1 phase. The elevated apoptotic ratio was caused by up-regulation of apoptosis-related proteins caspase-3, caspase-9 and bcl-2, in both dose- and time-dependent manners.
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Yuanfeng
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Qingchun
authors.initials: Q
authors.lastname: Xu
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Guoyuan
authors.initials: G
authors.lastname: Liu
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Huang
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Weiqiang
authors.initials: W
authors.lastname: Lin
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Yueying
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Zepai
authors.initials: Z
authors.lastname: Chi
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Shaochuan
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Kaijian
authors.initials: K
authors.lastname: Lan
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Jiahua
authors.initials: J
authors.lastname: Lin
authors.affiliation: Department of Urology, Shantou Central Hospital Swatow 515031, Guangdong, China.
authors.forename: Yonghai
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005434:Flow Cytometry; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D008297:Male; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C012589:trichostatin A; D006655:Histone Deacetylases
keywords: HDAC inhibitor; Histone deacetylase; prostate carcinoma
references.citation: Cell Cycle. 2007 Jun 1;6(11):1324-8
references.pmid: 17568193
references.citation: Br J Cancer. 2008 Feb 12;98(3):604-10
references.pmid: 18212746
references.citation: Anticancer Res. 2013 Apr;33(4):1351-60
references.pmid: 23564772
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):840-50
references.pmid: 19188154
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2003;23(4):359-61
references.pmid: 15015635
references.citation: Prostate. 2010 Jun 1;70(8):889-98
references.pmid: 20127736
references.citation: J Am Chem Soc. 2010 Aug 11;132(31):10842-6
references.pmid: 20614936
references.citation: Biochem Biophys Res Commun. 2011 Jan 28;404(4):915-21
references.pmid: 21184735
references.citation: Clin Cancer Res. 2001 Apr;7(4):971-6
references.pmid: 11309348
references.citation: Mol Cell Biol. 2007 Jul;27(13):4784-95
references.pmid: 17470557
references.citation: Lung Cancer. 2011 Nov;74(2):300-4
references.pmid: 21466904
references.citation: Biomed Pharmacother. 2013 Jun;67(5):407-15
references.pmid: 23583193
references.citation: Curr Med Chem. 2003 Nov;10(22):2351-8
references.pmid: 14529478
references.citation: Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906
references.pmid: 19721249
references.citation: Int J Cancer. 2010 Sep 1;127(6):1332-46
references.pmid: 20049841
references.citation: Cancer Lett. 2009 Aug 8;280(2):192-200
references.pmid: 19345475
references.citation: Cancers (Basel). 2011 Mar 1;3(1):1383-404
references.pmid: 21544224
references.citation: Int J Oncol. 2003 May;22(5):1129-34
references.pmid: 12684681
references.citation: J Oral Pathol Med. 2011 Oct;40(9):706-14
references.pmid: 21457345
references.citation: Expert Opin Investig Drugs. 2010 Sep;19(9):1049-66
references.pmid: 20687783